InflaRx N.V. (IFRX)

NASDAQ
Currency in USD
0.814
-0.078(-8.74%)
Closed·
After Hours
0.8140.000(0.00%)
·
IFRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IFRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8000.893
52 wk Range
0.7112.815
Key Statistics
Edit
Prev. Close
0.892
Open
0.865
Day's Range
0.8-0.893
52 wk Range
0.711-2.815
Volume
405.98K
Average Volume (3m)
494.57K
1-Year Change
-45.28%
Book Value / Share
1.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IFRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.701
Upside
+354.71%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

InflaRx N.V. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Compare IFRX to Peers and Sector

Metrics to compare
IFRX
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.6x−0.5x
PEG Ratio
0.210.030.00
Price/Book
0.7x1.4x2.6x
Price / LTM Sales
401.5x7.0x3.2x
Upside (Analyst Target)
171.0%126.6%46.0%
Fair Value Upside
Unlock8.9%6.3%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.701
(+354.71% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.13 / -0.17
Revenue / Forecast
-- / 187.50K
EPS Revisions
Last 90 days

IFRX Income Statement

FAQ

What Is the InflaRx (IFRX) Stock Price Today?

The InflaRx stock price today is 0.81.

What Stock Exchange Does InflaRx Trade On?

InflaRx is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for InflaRx?

The stock symbol for InflaRx is "IFRX."

What Is the InflaRx Market Cap?

As of today, InflaRx market cap is 56.23M.

What Is InflaRx's Earnings Per Share (TTM)?

The InflaRx EPS (TTM) is -0.75.

When Is the Next InflaRx Earnings Date?

InflaRx will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is IFRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InflaRx Stock Split?

InflaRx has split 0 times.

How Many Employees Does InflaRx Have?

InflaRx has 74 employees.

What is the current trading status of InflaRx (IFRX)?

As of 15 Jul 2025, InflaRx (IFRX) is trading at a price of 0.81, with a previous close of 0.89. The stock has fluctuated within a day range of 0.80 to 0.89, while its 52-week range spans from 0.71 to 2.82.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.